Volume 10, Issue 2 (6-2022)                   JoMMID 2022, 10(2): 64-74 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sheykhsaran E, Ebrahimzadeh Leylabadlo H, Alinezhad F, Feizi H, Bannazadeh Baghi H. A New Insight into Nosocomial Infections: a Worldwide Crisis. JoMMID 2022; 10 (2) :64-74
URL: http://jommid.pasteur.ac.ir/article-1-397-en.html
A New Insight into Nosocomial Infections: a Worldwide Crisis
Elham Sheykhsaran , Hamed Ebrahimzadeh Leylabadlo , Farbod Alinezhad , Hadi Feizi , Hossein Bannazadeh Baghi
Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, 5166/15731 Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, 5166/15731 Tabriz, Iran; Department of Bacteriology, Faculty of Medicine, Tabriz University of Medical Sciences, 5166/15731 Tabriz, Iran
Abstract:   (1732 Views)
The term "Nosocomial" is attributed to the diseases acquired by the patient under medical care. Various microorganisms, including bacteria, viruses, and fungi, may contribute to developing nosocomial infections (NIs). Urinary tract infections (UTI), surgical-site infections (SSI), bloodstream infections (BSI), and pneumonia are the most well-known instances. We investigated various aspects of NIs and the main causative agents of NIs, particularly bacteria, antibiotic resistance, crucial viral infections in hospitals, and a brief survey of fungal infections. It was concluded that specific human body tissues such as those in the lungs and urinary tract are more likely to be a target for nosocomial pathogens. The fatalities associated with these infections, particularly in the intensive care unit (ICU), are serious concerns, and transmission by health facilities has become a primary medical issue because of its spread into the community. Another medical point is antibiotic resistance which is a leading cause of prolonged periods of hospitalization and makes the treatment procedure harder and costlier. Additionally, measures to prevent the spread of NIs and minimize the economic loss are discussed. All physicians and medical students must be updated about different kinds of these infections, their causative agents, challenges, and how to deal with them to reduce the consequences and improve public health.
Keywords: Nosocomial infections, Antibiotic resistance, Bacterial and viral infections, Prevention and control
Full-Text [PDF 850 kb]   (755 Downloads)    
Type of Study: Review article | Subject: Other
Received: 2021/09/21 | Accepted: 2022/06/11 | Published: 2022/06/8
References
1. Miller MA, Hyland M, Ofner-Agostini M, Gourdeau M, Ishak M. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol. 2002; 23 (3): 137-40. [DOI:10.1086/502023]
2. Khan HA, Baig FK, Mehboob R. Nosocomial infections: Epidemiology, prevention, control and surveillance. Asian Pac J Trop Biomed. 2017; 7 (5): 478-82. [DOI:10.1016/j.apjtb.2017.01.019]
3. Vonberg R-P, Weitzel-Kage D, Behnke M, Gastmeier P. Worldwide Outbreak Database: the largest collection of nosocomial outbreaks. Infection. 2011; 39 (1): 29-34. [DOI:10.1007/s15010-010-0064-6]
4. Bereket W, Hemalatha K, Getenet B, Wondwossen T, Solomon A, Zeynudin A, et al. Update on bacterial nosocomial infections. Eur Rev Med Pharmacol Sci. 2012; 16 (8): 1039-44.
5. Khazaei S, Khazaei S, Ayubi E. Importance of Prevention and Control of Nosocomial Infections in Iran. Iran J Public Health. 2018; 47 (2): 307-8.
6. Podschun R, Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev. 1998; 11 (4): 589-603. [DOI:10.1128/CMR.11.4.589]
7. Brachman PS, Dan BB, Haley RW, Hooton TM, Garner JS, Allen JR. Nosocomial surgical infections: incidence and cost. Surg Clin North Am. 1980; 60 (1): 15-25. [DOI:10.1016/S0039-6109(16)42030-X]
8. Nichols R.L. Preventing surgical site infections: a surgeon's perspective. Emerge Infect Dis. 2011; 7 (2): 220-4. [DOI:10.3201/eid0702.010214]
9. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39 (3):. 309-17. [DOI:10.1086/421946]
10. Salata RA, Lederman MM, Shlaes DM, Jacobs MR, Eckstein E, Tweardy D, et al. Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. Am Rev Respir Dis. 1987; 135 (2): 426-32.
11. Fagon, J, Patrick H, Haas DW, Torres A, Gibert C, Cheadle WG, et al. Treatment of Gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med. 2000; 161 (3): 753-62. [DOI:10.1164/ajrccm.161.3.9904115]
12. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN, et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis. 2005; 52 (3): 187-93. [DOI:10.1016/j.diagmicrobio.2005.05.004]
13. Khan HA, Ahmad A, Mehboob R. Nosocomial infections and their control strategies. Asian Pac J Trop Biomed. 2015; 5 (7): 509-14. [DOI:10.1016/j.apjtb.2015.05.001]
14. Pitout, JDD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae: a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015; 59 (10): 5873-84. [DOI:10.1128/AAC.01019-15]
15. Sikora A, Zahra F. Nosocomial infections. StatPearls [Internet], 2021.
16. Burke JP. Infection control--a problem for patient safety. N Engl J Med. 2003; 348 (7): 651-6. [DOI:10.1056/NEJMhpr020557]
17. Klevens RM, Edwards JR, Richards Jr CL, Horan TC, Gaynes RP, Pollock DA, et al. Estimating healthcare-associated infections and deaths in US hospitals, 2002. Public Health Rep. 2007; 122 (2): 160-6. [DOI:10.1177/003335490712200205]
18. Leylabadlo HE, Samadi Kafil H, Aghazadeh M, Hazratian T. Nosocomial oral myiasis in ICU patients: occurrence of three sequential cases. GMS Hyg Infect Control. 2015; 10.
19. Bennett JV. Nosocomial infections due to Pseudomonas. J Infect Dis. 1974; 130 (Supplement): 4-7. [DOI:10.1093/infdis/130.Supplement.S4]
20. Mendiola-So M, Larson RE, Vernier D. A systematic review of whirlpool as an adjunctive treatment for cellulitis. Wound Med. 2017; 19: 47-74. [DOI:10.1016/j.wndm.2017.10.001]
21. Mardaneh J, Soltan Dallal MM. Isolation and identification Enterobacter asburiae from consumed powdered infant formula milk (PIF) in the neonatal intensive care unit (NICU). Acta Med Iran. 2016; 54 (1): 39-43.
22. Bing-Yuanab,Yun-Hui Zhangb, Nancy H.L.Leungc, Benjamin J.Cowlingc, Zi-Feng Yang. Role of viral bioaerosols in nosocomial infections and measures for prevention and control. J Aerosol Sci. 2018; 117: 200-11. [DOI:10.1016/j.jaerosci.2017.11.011]
23. Lax S, Gilbert JA. Hospital-associated microbiota and implications for nosocomial infections. Trends Mol Med. 2015; 21 (7): 427-32. [DOI:10.1016/j.molmed.2015.03.005]
24. Vasoo S, Barreto JN, Tosh PK. Emerging issues in Gram-negative bacterial resistance: an update for the practicing clinician. in Mayo Clinic Proceedings. 2015; 90 (3): 395-403.. [DOI:10.1016/j.mayocp.2014.12.002]
25. Harris PNA, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015; 15 (4): 475-85. [DOI:10.1016/S1473-3099(14)70950-8]
26. Gaynes R, Edwards JR. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis. 2005; 41 (6): 848-54. [DOI:10.1086/432803]
27. Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018; 18 (3): 285-95. [DOI:10.1016/S1473-3099(17)30747-8]
28. O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015; 8: 217-30. [DOI:10.2147/IDR.S54125]
29. Paterson DL. Resistance in Gram-negative bacteria: Enterobacteriaceae. Am J Infect. 2006; 119 (6 Suppl 1): S20-8. [DOI:10.1016/j.amjmed.2006.03.013]
30. Devrim F, Gülfidan G, Gözmen S, Demirağ B, Oymak Y, Yaman Y, et al. Comparison of the BD GeneOhm VanR assay and a chromogenic agar-based culture method in screening for vancomycin-resistant enterococci in rectal specimens of pediatric hematology-oncology patients. Turk J Pediatr Dis. 2015; 57 (2): 161-6.
31. Puchter L, Chaberny IF, Schwab F, Vonberg RF, Bange FC, Ebadi E. Economic burden of nosocomial infections caused by vancomycin-resistant enterococci. Antimicrob Resist Infect Control. 2018; 7 (1): 1. [DOI:10.1186/s13756-017-0291-z]
32. Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, Chen H, et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol. 2016; 35 (10): 1679-89. [DOI:10.1007/s10096-016-2710-0]
33. Ebrahimzadeh Leylabadlo H, Pourlak T, Zahedi Bialvaei A, Aghazadeh M, Asgharzadeh M, Samadi Kafil, et al. Extended-spectrum beta-lactamase producing Gram negative bacteria in Iran: a review. Afr J Infect Dis. 2017; 11 (2): 39-53. [DOI:10.21010/ajid.v11i2.6]
34. Rezai MS, Salehifar E, Rafiei A, Langaee T, Rafati M, Shafahi K, et al. Characterization of multidrug resistant extended-spectrum beta-lactamase-producing Escherichia coli among uropathogens of pediatrics in North of Iran. Biomed Res Int. 2015; 309478. [DOI:10.1155/2015/309478]
35. Anago E, Ayi-Fanou L, Akpovi CD, Hounkpe WB, Tchibozo MAD, Bankole HS, et al. Antibiotic resistance and genotype of beta-lactamase producing Escherichia coli in nosocomial infections in Cotonou, Benin. Ann Clin Microbiol. 2015; 14 (1): 5. [DOI:10.1186/s12941-014-0061-1]
36. Cho YH, Jung S Il, Chung HC, Yu HS, Hwang EC, Kim SO, et al. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin. Int Urol Nephrol. 2015; 47 (7): 1059-66. [DOI:10.1007/s11255-015-1018-9]
37. Sotgiu G, Are BM, Pesapane L, Palmieri A, Muresu N, Cossu A, et al. Nosocomial transmission of carbapenem-resistant Klebsiella pneumoniae in an Italian university hospital: a molecular epidemiological study. J Hosp Infect. 2018; 99 (4): 413-8. [DOI:10.1016/j.jhin.2018.03.033]
38. Zhang Y, Wang Q, Yin Y, Chen H, Jin L, Gu b, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE Network. Antimicrob Agents Chemother. 2018; 62 (2): 1882-17. [DOI:10.1128/AAC.01882-17]
39. Kim SB, Jeon YD, Kim JH, Kim JK, Ann HW, Choi H, et al. Risk factors for mortality in patients with Serratia marcescens bacteremia. Yonsei Med J. 2015; 56 (2): 348-54. [DOI:10.3349/ymj.2015.56.2.348]
40. Maki DG, Hennekens CG, Phillips CW, Shaw WV, Bennett JV. Nosocomial urinary tract infection with Serratia marcescens: an epidemiologic study. J Infect Dis. 1973; 128 (5): 579-87. [DOI:10.1093/infdis/128.5.579]
41. Su, LH, Ou JT, Leu HS, Chiang PC, Chiu YP, Chia JH, et al. Extended epidemic of nosocomial urinary tract infections caused by Serratia marcescens. J Clin Microbiol. 2003; 41 (10): 4726-32. [DOI:10.1128/JCM.41.10.4726-4732.2003]
42. Soltani J, Poorabbas B, Miri N, Mardaneh J. Health care associated infections, antibiotic resistance and clinical outcome: A surveillance study from Sanandaj, Iran. World J Clin Cases. 2016; 4 (3): 63-70. [DOI:10.12998/wjcc.v4.i3.63]
43. Mitov I, Strateva T, Markova B. Prevalence of virulence genes among Bulgarian nosocomial and cystic fibrosis isolates of Pseudomonas aeruginosa. Braz J Microbiol. 2010; 41 (3): 588-95. [DOI:10.1590/S1517-83822010000300008]
44. Winkler ML, Papp-Wallace KM, Hujer AM, Domitrovic TN, Hujer KM, Hurless KN, et al. Unexpected challenges in treating multidrug-resistant Gram-negative bacteria: resistance to ceftazidime-avibactam in archived isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2015; 59 (2): 1020-9. [DOI:10.1128/AAC.04238-14]
45. Kohlenberg A, Schwab F, Behnke M, Geffers C, Gastmeier P. Pneumonia associated with invasive and noninvasive ventilation: an analysis of the German nosocomial infection surveillance system database. Intensive Care Med. 2010; 36 (6): 971-8. [DOI:10.1007/s00134-010-1863-z]
46. Grasselli G, Scaravilli V, Di Bella S, Biffi S, Bombino M, Patroniti N, et al. Nosocomial infections during extracorporeal membrane oxygenation: Incidence, etiology, and impact on patients' outcome. Crit Care Med. 2017; 45 (10): 1726-33. [DOI:10.1097/CCM.0000000000002652]
47. Dai T, Gupta A, Huang YY, Yin R, Murray CK, Vrahas MS, et al. Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action. Antimicrob Agents Chemother. 2013; 57 (3): 1238-45. [DOI:10.1128/AAC.01652-12]
48. Bassetti M, Vena A, Croxatto A, Righi E, Guery B. How to manage Pseudomonas aeruginosa infections. Drugs context. 2018; 7: 212527. [DOI:10.7573/dic.212527]
49. Micek ST, Wunderink RG, Kollef MH, Chen C, Rello L, Chastre J, et al. An international multicenter retrospective study of Pseudomonas aeruginosa nosocomial pneumonia: impact of multidrug resistance. Crit Care. 2015; 19 (1): 219. [DOI:10.1186/s13054-015-0926-5]
50. Thomson JM, Bonomo RA. The threat of antibiotic resistance in Gram-negative pathogenic bacteria: β-lactams in peril! Curr Opin Microbiol. 2005; 8 (5): 518-24. [DOI:10.1016/j.mib.2005.08.014]
51. Van Eldere J. Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections. J Antimicrob Chemother. 2003; 51 (2): 347-52. [DOI:10.1093/jac/dkg102]
52. Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa-Mechanisms, epidemiology and evolution. Drug Resist Updat. 2019; 44: 100640. [DOI:10.1016/j.drup.2019.07.002]
53. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 1993; 6 (4): 428-42. [DOI:10.1128/CMR.6.4.428]
54. Lari AR, Alaghehbandan R. Nosocomial infections in an Iranian burn care center. Burns. 2000; 26 (8): 737-40. [DOI:10.1016/S0305-4179(00)00048-6]
55. Estahbanati HK, Kashani PP, Ghanaatpisheh F. Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics. Burns. 2002; 28 (4): 340-8. [DOI:10.1016/S0305-4179(02)00024-4]
56. Almasaudi SB. Acinetobacter spp. as nosocomial pathogens: Epidemiology and resistance features. Saudi J Biol Sci. 2018; 25 (3): 586-96. [DOI:10.1016/j.sjbs.2016.02.009]
57. Cisneros JM, Rodríguez-Baño J. Nosocomial bacteremia due to Acinetobacter baumannii: epidemiology, clinical features and treatment. Clin Microbiol Infect. 2002; 8 (11): 687-93. [DOI:10.1046/j.1469-0691.2002.00487.x]
58. Gonzalez-Villoria AM Valverde-Garduno V. Antibiotic-resistant Acinetobacter baumannii increasing success remains a challenge as a nosocomial pathogen. J Pathog. 2016: 7318075. [DOI:10.1155/2016/7318075]
59. Sieniawski K, Kaczka K, Rucińska M, Gagis L, Pomorski L. Acinetobacter baumannii nosocomial infections. Pol J Surg. 2013; 85 (9): 483-90. [DOI:10.2478/pjs-2013-0075]
60. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-WittelI M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003; 36 (9): 1111-8. [DOI:10.1086/374337]
61. Labarca J.A, Costa Salles MJ, Seas C, Guzmán-Blanco M. Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America. Crit Rev Microbiol. 2016; 42 (2): 276-92.
62. Gulen TA, Guner R, Celikbilek N, Keske S, Tasyaran M. Clinical importance and cost of bacteremia caused by nosocomial multi drug resistant Acinetobacter baumannii. Int J Infect Dis. 2015; 38: 32-5. [DOI:10.1016/j.ijid.2015.06.014]
63. Steven Y C Tong, Joshua S Davis, Emily Eichenberger, Thomas L Holland, Vance G Fowler Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015; 28 (3): 603-61. [DOI:10.1128/CMR.00134-14]
64. Hasani A, Asadi Faezi N, Ahangarzadeh Rezaee M, Sheykhsaran E, Darabi N, Ebrahimzadeh Leylabadlo H. Determination of Antimicrobial Resistance Patterns in Bloodstream Infections-Isolated Bacteria From a University Tertiary Hospital Patients. Int J Enteric Pathog. 2019; 7 (2): 49-54. [DOI:10.15171/ijep.2019.12]
65. Abad HEK, Sadeghi J, Aghazadeh M, Ahangarzadeh Rezaee M, Samadi Kafil H, Ahangar Oskouee M, et al. Frequency of fnbA, fnbB, hla and cna genes in Staphylococcus aureus isolates obtained from blood cultures and their antimicrobial susceptibility pattern in Tabriz, Iran. Arch Pharm Pract. 2020; 11 (S1): 137-43.
66. Zorgani A, Abofayed A, Glia A, Albarbar A, Hanish S. Prevalence of device-associated Nosocomial infections caused by Gram-negative bacteria in a trauma intensive care unit in Libya. Oman Med J. 2015; 30 (4): 270-5. [DOI:10.5001/omj.2015.54]
67. Boyce JM, White RL, Causey WA, Lockwood WR. Burn units as a source of methicillin-resistant Staphylococcus aureus infections. Jama. 1983; 249 (20): 2803-7. [DOI:10.1001/jama.1983.03330440041029]
68. Graffunder EM, Venezia R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. Antimicrob Chemother. 2002; 49 (6): 999-1005. [DOI:10.1093/jac/dkf009]
69. Valaperta R, Rosa Tejada M, Frigerio M, Moroni A, Ciulla E, Cioffi S, et al. Staphylococcus aureus nosocomial infections: the role of a rapid and low-cost characterization for the establishment of a surveillance system. New Microbiol. 2010; 33 (3): 223-32.
70. M Melzer, S J Eykyn, W R Gransden, S Chinn. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis. 2003; 37 (11): 1453-60. [DOI:10.1086/379321]
71. John J Engemann, Yehuda Carmeli, Sara E Cosgrove, Vance G Fowler, Melissa Z Bronstein, Sharon L Trivette, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003; 36 (5): 592-8. [DOI:10.1086/367653]
72. G Lina, Y Piémont, F Godail-Gamot, M Bes, M O Peter, V Gauduchon., et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999; 29 (5): 1128-32. [DOI:10.1086/313461]
73. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med. 2002; 136 (11): 834-44. [DOI:10.7326/0003-4819-136-11-200206040-00013]
74. Carmeli Y, Armstrong J, J Laud P, Newell P, Stone S, Wardman, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016; 16 (6): 661-73. [DOI:10.1016/S1473-3099(16)30004-4]
75. Sheykhsaran E, Bannazadeh Baghi H, Soroush Barhaghi MH, Alizadeh N, Memar MY et al. The rate of resistance to tetracyclines and distribution of tetA, tetB, tetC, tetD, tetE, tetG, tetJ and tetY genes in Enterobacteriaceae isolated from Azerbaijan, Iran during 2017. J Physiol Pharmacol. 2018; 22 (3): 205-12.
76. Bin Zaman S, Awlad Hussain M, Nye R, Mehta V, Taib Mamun K, Hossain N. A review on antibiotic resistance: alarm bells are ringing. Cureus, 2017; 9 (6); e1403. [DOI:10.7759/cureus.1403]
77. Sheykhsaran E, Baghi Hossein B, Soroush Mohammad H, Ghotaslou R . An overview of tetracyclines and related resistance mechanisms. Rev Med Microbiol. 2019; 30 (1): 69-75. [DOI:10.1097/MRM.0000000000000154]
78. Lalehzadeh A, Soroush MH, Sadeghi J, Ahangarzadeh Rezaee M, Pirzadeh T, Yeganeh Sefidan F, et al . Determination of fosfomycin resistant Enterobacteriaceae in isolates and frequency of fos genes in Tabriz Hospitals during 2018. J Biochem Tech. 2019; 10 (2): 143-8.
79. Economou V, P Gousia. Agriculture and food animals as a source of antimicrobial-resistant bacteria. Infect Drug Resist. 2015; 8: 49-61. [DOI:10.2147/IDR.S55778]
80. Rachel B. Slayton, Damon Toth, Bruce Y. Lee, Windy Tanner, Sarah M. Bartsch, Karim Khader, et al. Vital signs: estimated effects of a coordinated approach for action to reduce antibiotic-resistant infections in health care facilities - United States. MMWR Morb Mortal Wkly Rep. 2015; 64 (30): 826-31. [DOI:10.15585/mmwr.mm6430a4]
81. Wang Y, Li X, Ge T, Xiao Y, Liao Y, Cui Y, et al. Probiotics for prevention and treatment of respiratory tract infections in children: A systematic review and meta-analysis of randomized controlled trials. Medicine. 2016; 95 (31): e4509. [DOI:10.1097/MD.0000000000004509]
82. Aitken C, DJ Jeffries. Nosocomial spread of viral disease. Clin Microbiol Rev. 2001; 14 (3): 528-46. [DOI:10.1128/CMR.14.3.528-546.2001]
83. Hall CB. Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended. Clin Infect Dis. 2000; 31 (2): 590-6. [DOI:10.1086/313960]
84. D L George. Nosocomial viral pneumonia in the intensive care unit. Clin Chest Med. 1995; 16 (1): 29-44. [DOI:10.1016/S0272-5231(21)00977-1]
85. Faezi NA, Zahedi Bialvaei A, Ebrahimzadeh Leylabadlo H, Soleimani H, Yousefi M, Samadi Kafil H. Viral infections in patients with acute respiratory infection in Northwest of Iran. Mol Gen Microbiol Virol. 2016; 31 (3): 163-7. [DOI:10.3103/S0891416816030046]
86. Lehners N, Tabatabai J, Prifert CH, Wedde M, Puthenparambil J, Weissbrich B, et al. Long-term shedding of influenza virus, parainfluenza virus, respiratory syncytial virus and nosocomial epidemiology in patients with hematological disorders. PLoS One. 2016; 11 (2): e0148258. [DOI:10.1371/journal.pone.0148258]
87. Vanhems P, T Bénet, E Munier-Marion. Nosocomial influenza: encouraging insights and future challenges. Curr Opin Infect Dis. 2016; 29 (4): 366-72. [DOI:10.1097/QCO.0000000000000287]
88. Sheykhsaran E, N Hemmat, HB Baghi. Influenza A virus and related secondary bacterial infections. Rev Med Microbiol. 2018; 29: 205-11 [DOI:10.1097/MRM.0000000000000164]
89. Frenzel E, Chemaly RF, Ariza-Heredia E, Jiang Y, P Shah D, Thomas G, et al. Association of increased influenza vaccination in health care workers with a reduction in nosocomial influenza infections in cancer patients. Am J Infect Control. 2016; 44 (9): 1016-21. [DOI:10.1016/j.ajic.2016.03.024]
90. A Gagneur, J Sizun, S Vallet, M C Legr, B Picard, P J Talbot. Coronavirus-related nosocomial viral respiratory infections in a neonatal and paediatric intensive care unit: a prospective study. J Hosp Infect. 2002; 51 (1): 59-64. [DOI:10.1053/jhin.2002.1179]
91. Sarkesh A, Daei Sorkhabi A, Sheykhsaran E, Alinezhad F, Mohammadzadeh N, Hemmat N, et al. Extrapulmonary clinical manifestations in COVID-19 patients. Am J Trop Med. 2020; 103 (5): 1783-96. [DOI:10.4269/ajtmh.20-0986]
92. Abbas M, Nunes TR, Martischang R, Zingg W, Iten I, Pittet D, et al. Nosocomial transmission and outbreaks of coronavirus disease 2019: the need to protect both patients and healthcare workers. Antimicrob Resist Infect Control. 2021; 10 (1): 1-13. [DOI:10.1186/s13756-020-00875-7]
93. Oke J, C Heneghan. Global COVID-19 case fatality rates-CEBM. URL https://www. cebm. net/covid-19/global-covid-19-case-fatality-rates [accessed 29 March 2020], 2020.
94. Quah P, A Li, J Phua. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic review of the emerging literature. Critic Care. 2020; 24 (1): 285. [DOI:10.1186/s13054-020-03006-1]
95. S C Y Wong, R T-S Kwong, T C Wu, J W M Chan, M Y Chu, S Y Lee, et al. Risk of nosocomial transmission of coronavirus disease 2019: an experience in a general ward setting in Hong Kong. J Hosp Infect. 2020; 105 (2): 119-27. [DOI:10.1016/j.jhin.2020.03.036]
96. Zboromyrska Y, J Vila. Advanced PCR-based molecular diagnosis of gastrointestinal infections: challenges and opportunities. Expert Rev Mol Diagn. 2016; 16 (6): 631-40. [DOI:10.1586/14737159.2016.1167599]
97. Ben A Lopman, Mark H Reacher, Ian B Vipond, Dawn Hill, Christine Perry, Tracey Halladay, et al. Epidemiology and cost of nosocomial gastroenteritis, Avon, England, 2002-2003. Emerg Infect Dis. 2004. 10 (10): 1827-34. [DOI:10.3201/eid1010.030941]
98. Adissa Tran, Déborah Talmud, Benoît Lejeune, Nicolas Jovenin, Fanny Renois, Christopher Payan, et al. Prevalence of rotavirus, adenovirus, norovirus, and astrovirus infections and coinfections among hospitalized children in northern France. J Clin Microbiol. 2010; 48 (5): 1943-6. [DOI:10.1128/JCM.02181-09]
99. Olivier Gleizes, Ulrich Desselberger, Vladimir Tatochenko, Carlos Rodrigo, Nuran Salman, Zsofia Mezner. Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease. Pediatr Infect Dis J. 2006; 25 (1): 12-21. [DOI:10.1097/01.inf.0000197563.03895.91]
100. Diem-Lan Vu, Albert Bosch, Rosa M Pintó, Susana Guix. Epidemiology of classic and novel human astrovirus: gastroenteritis and beyond. Viruses. 2017; 9 (2): 33. [DOI:10.3390/v9020033]
101. Breathnach AS. Nosocomial infections and infection control. Medicine, 2013; 41 (11): 649-53. [DOI:10.1016/j.mpmed.2013.08.010]
102. G Di Perri, M Cruciani, M C Danzi, R Luzzati, G De Checchi, M Malena, et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. Lancet. 1989; 334 (8678-8679): 1502-4. [DOI:10.1016/S0140-6736(89)92942-5]
103. U Frank, F D Daschner, G Schulgen, J Mills. Incidence and epidemiology of nosocomial infections in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997; 25 (2): 318-20. [DOI:10.1086/514553]
104. D K Henderson, A J Saah, B J Zak, R A Kaslow, H C Lane, T Folks, et al., Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). N Engl J Med.1985; 312 (1): 644-7.
105. Nicolas Ponroy, Aline Taveira, Nicolas J Mueller, Anne-Laure Millard. Statins demonstrate a broad anti‐cytomegalovirus activity in vitro in ganciclovir‐susceptible and resistant strains. J Med Virol. 2015; 87 (1): 141-53. [DOI:10.1002/jmv.23998]
106. Ané Büchner, Nicolette M Du Plessis, David T Reynders, Fareed E Omar, Simnikiwe H Mayaphi, Ahmad F Haeri Mazanderani, et al. Nosocomial outbreak of hepatitis B virus infection in a pediatric hematology and oncology unit in South Africa: Epidemiological investigation and measures to prevent further transmission. Pediatr Blood Cancer. 2015; 62 (11): 1914-19. [DOI:10.1002/pbc.25605]
107. Hwang JP, HA Torres. Hepatitis B virus and hepatitis C virus infection in immunocompromised patients. Curr Opin Infect Dis. 2018; 31 (6): 535-41. [DOI:10.1097/QCO.0000000000000500]
108. Uga Dumpis, Zanna Kovalova, Juris Jansons, Liene Cupane, Irina Sominskaya, Marija Michailova, et al. An outbreak of HBV and HCV infection in a pediatric oncology ward: epidemiological investigations and prevention of further spread. J Med Virol. 2003; 69 (3): 331-8. [DOI:10.1002/jmv.10293]
109. P M Schneeberger, I Keur, A M van Loon, D Mortier, K O de Coul, A V van Haperen, et al. The prevalence and incidence of hepatitis C virus infections among dialysis patients in the Netherlands: a nationwide prospective study. J Infect Dis. 2000; 182 (5): 1291-9. [DOI:10.1086/315869]
110. N Petrosillo, P Gilli, D Serraino, P Dentico, A Mele, P Ragni, et al. Prevalence of infected patients and understaffing have a role in hepatitis C virus transmission in dialysis. Am J Kidney Dis. 2001; 37 (5): 1004-10. [DOI:10.1016/S0272-6386(05)80017-4]
111. Shears P, T O'Dempsey. Ebola virus disease in Africa: epidemiology and nosocomial transmission. J Hosp Infect. 2015; 90 (1): 1-9. [DOI:10.1016/j.jhin.2015.01.002]
112. Kanamori H, Rutala WA, Sickbert-Bennett EE, Weber DJ. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis. 2015; 61 (3): 433-44. [DOI:10.1093/cid/civ297]
113. Fridkin SK, WR Jarvis. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev. 1996; 9 (4): 499-511. [DOI:10.1128/CMR.9.4.499]
114. D M Dixon, M M McNeil, M L Cohen, B G Gellin, J R La Montagne. Fungal infections: a growing threat. Public Health Rep. 1996; 111 (3): 226-35.
115. Kramer A, I Schwebke, G Kampf. How long do nosocomial pathogens persist on inanimate surfaces? A systematic review. BMC Infect Dis. 2006; 6 (1): 130. [DOI:10.1186/1471-2334-6-130]
116. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis. 1995; 20 (6): 1526-30. [DOI:10.1093/clinids/20.6.1526]
117. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis. 1996; 22 Suppl 2: 89-94. [DOI:10.1093/clinids/22.Supplement_2.S89]
118. Richardson MD. Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother. 2005; 56 (suppl_1): i5-i11. [DOI:10.1093/jac/dki218]
119. Ana Belkin, Zeala Gazit, Nathan Keller, Ronen Ben-Ami, Anat Wieder-Finesod, Ana Novikov. Candida auris infection leading to nosocomial transmission, Israel, 2017. Emerg Infect Dis. 2018; 24 (4): 801-4. [DOI:10.3201/eid2404.171715]
120. Spivak ES, KE Hanson. Candida auris: an emerging fungal pathogen. J Clin Microbiol. 2018; 56 (2): e01588-17. [DOI:10.1128/JCM.01588-17]
121. K Y Chen, S C Ko, P R Hsueh, K T Luh, P C Yang. Pulmonary fungal infection: emphasis on microbiological spectra, patient outcome, and prognostic factors. Chest. 2001; 120 (1): 177-84. [DOI:10.1378/chest.120.1.177]
122. Perlroth J, B Choi, B Spellberg. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol J. 2007; 45 (4): 321-46. [DOI:10.1080/13693780701218689]
123. Kordbacheh P, Zaini F, Kamali P, Ansari K, Safara M. Study on the Sources of Nosocomial Fungal Infections at Intensive Care Unit and Transplant Wards at a Teaching Hospital in Tehran. Iran J Public Health. 2005; 34 (2): 1-8.
124. Bergogne-Berezin E. Current guidelines for the treatment and prevention of nosocomial infections. Drugs. 1999; 58 (1): 51-67. [DOI:10.2165/00003495-199958010-00005]
125. Dinkel RH, U Lebok. A survey of nosocomial infections and their influence on hospital mortality rates. J Hosp Infect. 1994; 28 (4): 297-304. [DOI:10.1016/0195-6701(94)90093-0]
126. YI W, Zhang Y, Zhang R. Economic Loss due to Hospital Infection: A Case Control Study. Chinese Journal of Nosocomiology. 2006; 10: 027.
127. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002; 113 (1): 5-13. [DOI:10.1016/S0002-9343(02)01054-9]
128. Bryan CS, KL Reynolds. Hospital-acquired bacteremic urinary tract infection: epidemiology and outcome. J Urol. 1984; 132 (3): 494-7. [DOI:10.1016/S0022-5347(17)49707-2]
129. T C Horan, D H Culver, R P Gaynes, W R Jarvis, J R Edwards, C R Reid. Nosocomial infections in surgical patients in the United States, January 1986-June 1992. Infect Control Hosp Epidemiol. 1993; 14 (2): 73-80. [DOI:10.2307/30147164]
130. Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention. Infect Control Hosp Epidemiol. 1996; 17 (8): 552-7. [DOI:10.2307/30141291]
131. R W Haley, D H Culver, J W White, W M Morgan, T G Emori, V P Munn, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol. 1985; 121 (2): 182-205. [DOI:10.1093/oxfordjournals.aje.a113990]
132. Jarvis WR. Benchmarking for prevention: the Centers for Disease Control and Prevention's National Nosocomial Infections Surveillance (NNIS) system experience. Infection. 2003; 31 Suppl 2: 44-8.
133. Sheykhsaran E, Hemmat N, Leylabadlo HE, Baghi HB. Bacterial and viral zoonotic infections: bugging the world. Rev Med Microbiol. 2022; 33 (1): 70-81. [DOI:10.1097/MRM.0000000000000273]
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.